tbuckley/cabot-search huggingface dataset:
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Authors: Douglas B. Johnson, Justin M. Balko, Margaret L. Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R. Alexander, Tyler L. Bloomer, Jason R. Becker, David A. Slosky, Elizabeth J. Phillips, Mark A. Pilkinton, Laura Craig-Owens, Nina Kola, Gregory Plautz, Daniel S. Reshef, Jonathan S. Deutsch, Raquel P. Deering, Benjamin A. Olenchock, Andrew H. Lichtman, Dan M. Roden, Christine E. Seidman, Igor J. Koralnik, Jonathan G. Seidman, Robert D. Hoffman, Janis M. Taube, Luis A. Diaz, Robert A. Anders, Jeffrey A. Sosman, Javid J. Moslehi
Journal: New England Journal of Medicine (2016)

Immune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy. We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab. In both patients, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with a robust presence of T-cell and macrophage infiltrates. Selective clonal T-cell populations infiltrating the myocardium were identical to those present in tumors and skeletal muscle. Pharmacovigilance studies show that myocarditis occurred in 0.27% of patients treated with a combination of ipilimumab and nivolumab, which suggests that our patients were having a rare, potentially fatal, T-cell-driven drug reaction. (Funded by Vanderbilt-Ingram Cancer Center Ambassadors and others.).
Protein Kinase C-Epsilon Is An Important Component of the Lyn Kinase Signaling Pathway in the Apoptotic Resistance of B- Chronic Lymphocytic Leukemia Cells.
Authors: Vamsidhar Velcheti, Srikanth Tamma, Zoe L Larned, Jyotsna Fuloria, Li Li, Francis R Rodwig, John T. Cole, Felipe Samaniego, Om Prakash
Journal: Blood (2008)
A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy
Authors: Elliott Vichinsky, Marcela Torres, Jonathan Glass, Caterina P Minniti, Stéphane Barrette, Dany Habr, Nicola Lynch, Yiyun Zhang, Beatrice Files
Journal: Blood (2011)
Src Family Kinase Inhibitor PP2 Enhances Differentiation Of Acute Promyelocytic Leukemia Cell Line Induced By Combination Of ATRA and Arsenic Trioxide
Authors: Kyoung Ha Kim, Hee-Jeong Cheong, Sook-Ja Kim, Jina Yoon, Han Jo Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan-Kyu Kim, Namsu Lee, Kyu Taeg Lee, Sung Kyu Park, Dae Sik Hong, Hee Sook Park, Jong-Ho Won
Journal: Blood (2013)
Differences in Patients with Progressive Versus Non-Progressive AML, CLL, or NHL: Implications for Proposed Bundled Payment Strategies
Authors: Stacey Dacosta Byfield, Nicole Engel-Nitz, Timothy Bancroft, Amy J Anderson, Carolina Reyes, Arliene Ravelo, Sarika Ogale, May Chen, Matthew J. Matasar
Journal: Blood (2015)
Development of Late over Early Full Donor Chimerism (FDC) Results in Improved Progression-Free and Overall Survival in Patients with Advanced Malignant Lymphomas Receiving Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: David T. Ting, Bimalangshu Dey, Ahmed Chaudhary, Christine Colby, Karen Power, Steven McAfee, Karen Ballen, Eyal Attar, Susan Saidman, Frederick Preffer, Robert Sackstein, Juanita Shaffer, Megan Sykes, Thomas R. Spitzer
Journal: Blood (2005)
Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias
Authors: Yashodhara Dasgupta, Mateusz Koptyra, Margaret Nieborowska-Skorska, Elisabeth Bolton Gillespie, Tomasz Stoklosa, Grazyna Hoser, Mariusz Wasik, Markus Muschen, Christine Richardson, Tomasz Skorski
Journal: Blood (2013)
Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study.
Authors: Violaine Safar, Thomas Gastinne, Noel Milpied, Hervé Maisonneuve, Nadine Morineau, Viviane Dubruille, Beatrice Mahé, Philippe Moreau, Henri Jardel, Lucie Planche, Philippe Moreau, Jean-Luc Harousseau, Steven Le Gouill
Journal: Blood (2008)
Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)
Authors: Susan o'Brien, Deborah A. Thomas, Maro Ohanian, Jeffrey L. Jorgensen, Partow Kebriaei, Elias Jabbour, Michael E. Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jorge E. Cortes, Luis Fayad, Robert Tarnai, Sa A. Wang, Richard Champlin, Anjali S. Advani, Hagop M. Kantarjian
Journal: Blood (2011)
Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.
Authors: Bilal Ahmed, Rima M. Saliba, Noman Ashraf, Floralyn Mendoza, Chitra Hosing, Thuy Flosser, Donna M. Weber, Michael Wang, Daniel R. Couriel, Uday Popat, Partow Kebriaei, Amin M. Alousi, Richard E. Champlin, Sergio A. Giralt, Muzaffar H. Qazilbash
Journal: Blood (2006)
Some Unusual Complications of Malignancies
Authors: Michelle A. Fanale, Steven R. Zeldenrust, Timothy J. Moynihan
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.19.4111 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12351608 Some Unusual Complications of Malignancies Case 2. Marantic Endocarditis in Advanced Cancer Michelle A. FanalexMichelle A. FanaleSearch for articles by this author , Steven R. ZeldenrustxSteven R. ZeldenrustSearch for articles by this author , Timothy J. MoynihanxTimothy J. MoynihanSearch for articles by this author Show More Mayo Clinic, Rochester, MN https://doi.org/10.1200/JCO.2002.20.19.4111 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells
Authors: Anita K Gandhi, Herve Avet-Loiseau, Michelle Waldman, Anjan Thakurta, Sharon L Aukerman, Gengxin Chen, Derek Mendy, Emily Rychak, Karen Miller, Svetlana Gaidarova, Michael Gonzales, Brian Cathers, Peter H Schafer, Tom O Daniel, Antonia Lopez-Girona, Rajesh Chopra
Journal: Blood (2012)
Abstract 10120: Increased Stroke Mortality Among Lean Japanese
Authors: Hisako Tsuji, Ichiro Shiojima
Journal: Circulation (2015)

Background: Several large cohort studies showed underweight was associated with an increased risk of death in Asians after major methodologic issues were addressed. We examined specific causes of death in lean Japanese of a general population. Methods: We studied 16,461 subjects (mean age 54±13 years, men 26%) who had the annual health checkup offered to adult citizens of Moriguchi city, Osaka, Japan in 1997. The subjects were divided into 5 groups according to body mass index (BMI) presented in the table. Proportional hazards regression analyses adjusted for age, sex, smoking status, drinking habit, history of CV disease, hypertension, diabetes, and hyperlipidemia were used to assess the association of BMI categories with mortality. Results: During a mean follow-up of 14.1±4.4 years, there were 1,939 deaths. Of those, there were 797 cancer deaths, 462 cardiovascular (CV) deaths including 114 coronary deaths, 156 stroke deaths with 88 ischemic stroke deaths. Hazard ratios (HR) relative to the BMI of 22.0-24.9 kg/m 2 group with 95% confidence intervals (CI) were presented in the table. Although underweight (&lt;18.0 kg/m 2 ) was not associated with cancer deaths, it was significantly associated with CV deaths (HR=1.92, 95%CI=1.33 to 2.78, p=0.0005) and stroke deaths (HR=2.02, 95%CI=1.07 to 3.81, p=0.0295). Among stroke deaths, ischemic stroke deaths tended to be higher in the underweight group (HR=1.95, 95%CI=0.90 to 4.26, p=0.0926). Conclusions: In the general Japanese population, underweight was associated with higher stroke mortality.
No Reduction of Ovarian Failure with the Use of GnRH-Analogues or Oral Contraceptives in Young Women Treated with Escalated BEACOPP for Advanced-Stage Hodgkin Lymphoma (HL). Final Results of the PROFE Trial, German Hodgkin Study Group (GHSG).
Authors: Karolin Behringer, Ludwig Wildt, Horst Mueller, Helmut-Werner Ott, Susanne Hofer, Volker Diehl, Beate van den Hoonard, Andreas Engert, Peter Borchmann
Journal: Blood (2009)
A Decade of Stem Cell Transplantation in Lymphoma: Single Center Experience and Outcome of 938 Consecutive Allogeneic and Autologous Hematopoietic Stem Cell Transplants Performed At John Theurer Cancer Center
Authors: Anthony R Mato, Andrew L Pecora, Scott D Rowley, Michele L Donato, Stuart L. Goldberg, Tatyana Feldman, David H. Vesole, Tania Zielonka, Theresa Amatucci, Alexandria Campaiola, Arun K Singavi, Clement Cousin, Andre Goy
Journal: Blood (2011)
Clinical verification of sensitivity to pre-operative chemotherapy androgen in case of receptor expressing positive TNBC
Authors: Yuka Asano, Shinichiro Kashiwagi, Kento Kurata, Satoru Noda, Hidemi Kawajiri, Tsutomu Takashima, Naoyoshi Onoda, Masahiko Osawa, Kosei Hirakawa
Journal: Annals of Oncology (2015)
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients
Authors: Jitka Fucikova, Iva Truxova, Michal Hensler, Etienne Becht, Lenka Kasikova, Irena Moserova, Sarka Vosahlikova, Jana Klouckova, Sarah E. Church, Isabelle Cremer, Oliver Kepp, Guido Kroemer, Lorenzo Galluzzi, Cyril Salek, Radek Spisek
Journal: Blood (2016)
THE QUANTIFICATION OF CHANGES IN CARDIORESPIRATORY FITNESS INDEPENDENT FROM CHANGES IN BODY MASS: ILLUSTRATION OF AN ALLOMETRIC APPROACH
Authors: L Lolli, AM Batterham, K L Weston, G Atkinson
Journal: British Journal of Sports Medicine (2016)

Both obesity and a low level of cardiorespiratory fitness (VO 2max ) are strong predictors of morbidity and mortality. Therefore, in any lifestyle intervention study, it is important to ascertain if any changes in VO 2max are clinically important, while considering any parallel changes in body mass and/or composition. Most researchers adopt a simple ratiometric approach to normalising VO 2max (ml·kg −1 ·min −1 ), even though this is associated with several important assumptions, which are rarely confirmed by researchers. Using data from the Activity Counselling Trial (ACT), we developed and applied a novel allometric approach for comparing normalised changes in VO 2max between different treatment arms. Overall, 874 participants were randomly allocated into advice only (n=292), assistance (n=293) and counselling group (n=289), respectively. A repeated-measures allometric model was adopted to adjust the changes in VO 2max for the concurrent changes in body mass and fat-free mass from baseline to 24-month follow-up. Magnitude thresholds for standardized differences in VO 2max of 0.20, 0.60, 1.20, 2.0 and 4.0 were considered as a small, moderate, large, very large and extremely large effect, respectively. The within-subjects allometric exponent (90% CL) for body mass was 0.46 (0.40 to 0.53) and 0.37 (0.31 to 0.43) in men and women, respectively. The respective fat-free mass exponents were 0.79 (0.71 to 0.87) and 0.64 (0.56 to 0.73). Ratio-scaled VO 2max increased 4.5% (2.1% to 7.0%) more in the assistance vs advice group. This increase was slightly smaller when allometrically scaled to body mass [3.9% (1.7% to 6.1%)] and fat-free mass [3.7% (1.5% to 6.0%)], although standardised mean differences were similar between approaches (≈ 0.2). Similar findings were obtained for the counselling vs advice groups. Changes in VO 2max were small in all study arms for men. Contrary to the original study report and subsequent citations, scaled intervention effects on cardiorespiratory fitness in the ACT are unlikely to be clinically important. Given the non-linear relationship between changes in body size and VO 2max , a within-subjects allometric modelling approach is recommended for accurately quantifying any intervention-induced effects in future studies.
The use of panitumumab (Pan) in patients (pts) with metastatic colorectal carcinoma (CRC) whose disease has progressed through treatment (Rx) with cetuximab (Cet)
Authors: C. L. Martel, M. V. McNamara
Journal: Journal of Clinical Oncology (2009)

e15142 Background: Both Pan and Cet have activity in the Rx of metastatic CRC. As they each target the epidermal growth factor receptor, and are believed to have the same mechanism of action, pts who fail Rx with one of these agents are generally not treated with the other. Methods: A retrospective chart review was performed of pts in our practice with metastatic CRC. The response to Pan of pts whose disease had progressed despite use of a Cet containing regimen was assessed. Results: We identified three pts who received Pan after failing Rx with Cet. Pt 1 was an 81 year old female who had discontinued Rx with 5- fluorouracil (5-FU) and leucovorin (Lcv) plus bevacizumab (bev); capecitabine; and irinotecan due to intolerance. She received Cet for 6 months with initial stable disease (SD) and subsequent progressive disease (PD). She was later treated with Pan for 6 months with slight shrinkage of her metastatic disease (SD by response evaluation criteria in solid tumors) and marked improvement of her performance status (PS) before eventual PD. Pt 2 was a 43 year old female who had eventual PD after Rx with oxaliplatin and capecitabine plus bev; irinotecan plus bev; and an experimental vaccine. She was treated with Cet for 6 months with a PR, followed by PD. She received Pan for 3 months, with improvement in her PS, decreased pain and a 45% decline in her carcinoembryonic antigen level, before eventual PD (no radiologic studies were obtained during Rx with Pan). Pt 3 was a 64 year old female whose prior Rx had included oxaliplatin plus infusional 5-FU and Lcv (FOLFOX), as well as irinotecan plus infusional 5-FU and Lcv (FOLFIRI) with Cet; the latter was continued for 3.5 months, with a best response of SD. She then received 4 doses of Pan, but had PD. Conclusions: Pan led to clinical improvement with objective evidence of disease stabilization or response in 2 of 3 pts in our practice who had previously failed Cet. Pan has meaningful, although modest, activity in pts with metastatic CRC whose disease has progressed through Cet. The use of Pan should be considered in pts who have failed Cet and who do not have other viable Rx options. No significant financial relationships to disclose.
Chest magnetic resonance imaging for pneumonia diagnosis in outpatients with lower respiratory tract infection
Authors: Hannu Syrjala, Markku Broas, Pasi Ohtonen, Airi Jartti, Eija Pääkkö
Journal: European Respiratory Journal (2016)

We assessed whether magnetic resonance imaging (MRI) is applicable for diagnosing pneumonia among adult outpatients with lower respiratory tract infection. Patients were recruited prospectively when they had symptoms for ≤7 days and fever ≥37.8 °C. The patients underwent high-resolution computed tomography (HRCT), MRI and chest radiography, which were repeated 1 month later if necessary, to verify pneumonia. The duration of MRI examination was 3–4 min. Among 77 patients, HRCT, MRI and radiography identified 32 (41.6%), 30 (39.0%) and 23 (29.9%) cases of pneumonia, respectively (p=0.001). MRI missed two HRCT-identified pneumonia cases due to motion artefacts. Chest radiography resulted in four false-positive pneumonia findings and MRI resulted in none. When HRCT was used as a reference, MRI had a sensitivity of 0.938 (95% CI 0.799–0.983) and specificity of 0.978 (95% CI 0.884–0.996) for the diagnosis of pneumonia, whereas the sensitivity and specificity for chest radiography were 0.719 (95% CI 0.546–0.844) and 0.911 (95% CI 0.793–0.965), respectively. MRI is an accurate, fast and effective method for diagnosing outpatient pneumonia, with better accuracy compared with chest radiography and almost similar accuracy compared with HRCT.
Commentary on microRNA Fingerprint in Human Epithelial Ovarian Cancer
Authors: Marilena V. Iorio, Carlo M. Croce
Journal: Cancer Research (2016)

See related article by Iorio et al., [Cancer Res 2007;67:8699–707][1] .

Visit the Cancer Research 75th Anniversary [timeline][2].

The highlighted article ([1][3]) described for the first time the miRNA aberrant expression in human epithelial ovarian cancer. Along with the miRNA profiling we
High Resolution Epigenomic Profiling of Loss of Heterozygosity in MDS Reveals an Important Role of DNA Methylation in Regulating Expression of Genes in the Deleted Regions of Chromosomes 5q, 7q and 20q.
Authors: D. Sohal, J. Opalinska, L. Zhou, P. Pahanish, E. Friedman, R. Thompson, K. Ye, M. Figueroa, A. Melnick, J. Greally, A. List, A. Verma
Journal: Blood (2007)
B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal Center B-Cell Subtype, Plus Self Antigen-Induced in the Activated B-Cell Subtype
Authors: Ondrej Havranek, Stefan Koehrer, Jingda Xu, Lisa Becker, Justin M Comer, Anusha R Karri, Zhiqiang Wang, Wencai Ma, Jason R Westin, Tomasz Zal, Jan A Burger, R Eric Davis
Journal: Blood (2015)
Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.
Authors: Patrick Stiff, Mary Fox-Geiman, Karen Kiley, Nancy Porter, Karen Rychlik, Donna Fletcher-Gonzalez, Amir Toor, Scott E. Smith, Tulio Rodriguez
Journal: Blood (2009)
Prognostic Factors of Reducing Relapse in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation From Related Donor for Acute Myeloid Leukemia: The Japan Society for Hematopoietic Cell Transplantation (JSHCT) AML Working Group
Authors: Shingo Yano, Hiroki Yokoyama, Rimei Nishimura, Takahiro Fukuda, Hiroyasu Ogawa, Kazuteru Ohashi, Heiwa Kanamori, Junji Tanaka, Hisashi Sakamaki, Yoshiko Atsuta, Akiyoshi Takami
Journal: Blood (2011)
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Authors: Yogesh S. Jethava, Alan Mitchell, Joshua Epstein, Maurizio Zangari, Shmuel Yaccoby, Erming Tian, Sarah Waheed, Rashid Khan, Xenofon Papanikolaou, Monica Grazziutti, Michele Cottler-Fox, Nathan Petty, Douglas Steward, Susan Panozzo, Clyde Bailey, Antje Hoering, John Crowley, Jeffrey Sawyer, Gareth Morgan, Bart Barlogie, Frits van Rhee
Journal: Clinical Cancer Research (2016)

Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk multiple myeloma were randomized between a standard arm (TT4-S) and a light arm (TT4-L). TT4-L employed one instead of two inductions and consolidations. To compensate for potential loss of efficacy of TT4-L, bortezomib and thalidomide were added to fractionated melphalan 50 mg/m2/d for 4 days.Results: Grade ≥3 toxicities and treatment-related mortalities were not reduced in TT4-L. Complete response (CR) rates were virtually identical (P = 0.2; TT4-S, 59%; TT4-L, 61% at 2 years), although CR duration was superior with TT4-S (P = 0.05; TT4-S, 87%; TT4-L, 81% at 2 years). With a median follow-up of 4.5 years, there was no difference in overall survival (OS) and progression-free survival (PFS). Whereas metaphase cytogenetic abnormalities (CAs) tended to be an adverse feature in TT4-S, as with predecessor TT trials, the reverse applied to TT4-L. Employing historical TT3a as training and TT3b as test set, 51 gene probes (GEP51) significantly differentiated the presence and absence of CA (q < 0.0001), seven of which function in DNA replication, recombination, and repair. Applying the GEP51 model to clinical outcomes, OS and PFS were significantly inferior with GEP51/CA in TT4-S; such a difference was not observed in TT4-L.Conclusions: We identified a prognostic CA-linked GEP51 signature, the adversity of which could be overcome by potentially synergizing anti-multiple myeloma effects of melphalan and bortezomib. These exploratory findings require confirmation in a prospective randomized trial. Clin Cancer Res; 23(11); 2665-72. ©2016 AACR.
CBL Mutations In Pediatric Acute Myelogenous Leukemia Are a Rare Event, a Report From the Children's Oncology Group.
Authors: Matthew A. Kutny, Kristen Miller, Todd A. Alonzo, Robert B. Gerbing, Phoenix A. Ho, Alan S. Gamis, Susana C. Raimondi, Betsy A. Hirsch, Soheil Meshinchi
Journal: Blood (2010)
B-Cell Epitope Mapping of Monoclonal Anti-Factor VIII C2 Domain Inhibitors: Identification of Amino Acids That Contribute Significant Antigen-Antibody Binding Affinity.
Authors: Jasper C. Lin, Jason T. Schuman, Shannon L. Meeks, John F. Healey, Arthur R. Thompson, Kathleen P. Pratt
Journal: Blood (2008)
The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis
Authors: Angela Dispenzieri, Morie A Gertz, Amy K Saenger, Martha Grogan, Shaji Kumar, Martha Q Lacy, Robert A Kyle, Nelson Leung, Steven Zeldenrust, Suzanne R Hayman, Francis K Buadi, Philip R. Greipp, S. Vincent Rajkumar, Stephen Russell, David Dingli, John A Lust, Allan Jaffe
Journal: Blood (2011)
Risk of treatment delay in patients suspected of sepsis with moderate to high risk criteria
Authors: Michael Eisenhut
Journal: BMJ (2016)

In the recently published NICE sepsis guidance the authors outline pathways of management stratified according to risk of severe illness and death.1 2 They recommend that patients with one moderate to high risk criterion without a definitive condition do not automatically receive early antibiotic administration within an hour but do undergo senior clinician review within three hours for consideration of antibiotics.

One such moderate to high risk criterion is behaving differently from usual. A child with fever and altered behaviour, however, could have encephalitis. The consensus guidelines of the Association …
Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
Authors: Jesus F San Miguel, Rudolf Schlag, Nuriet K Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Ivan Spicka, Maria Teresa Petrucci, Antonio Palumbo, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Maria-Victoria Mateos, Kenneth C Anderson, Dixie-Lee Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Paul Richardson
Journal: Blood (2008)
Modeling the Effects of Priming With the Whole-Cell Bordetella Pertussis Vaccine
Authors: Thomas Snelling, Peter McIntyre
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal